ClinicalTrials.gg
CompletedNCT00501852Updated May 8, 2012Results posted

Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

A Phase 2 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-05-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
46th of 73
83 · median 152
Started
2007
with 3 others
Phase 2
19 of 73
none open now
Registered
2nd of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 46th largest by enrollment, is one of 4 that started in 2007, is one of 19 in phase 2, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD, Age≥40 yrs, Glycopyrronium Bromide
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults aged ≥40 years, who have signed an Form prior to initiation of any study-related procedure.
  • Patients with moderate to severe according to the Gold Guidelines (2006).
  • Patients who have smoking history of at least 10 pack years. Ten pack-years is defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.
  • Patients with a post-bronchodilator (FEV1) ≥30% and \< 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) \< 0.7 at Visit 2. For non-Japanese patients predicted FEV1 should be calculated according to Quanjer predictive equations [Quanjer PH 1993], for Japanese patients predicted FEV1 should be calculated according to Japanese Respiratory Society predictive tables [Japan Respiratory Society 2001].

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).
  • Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to Visit 1 or between Visit 1 and Visit 3.
  • Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Patients who develop a respiratory tract infection during the screening period (up to Visit 3) must discontinue from the trial, but will be permitted to re-enroll at a later date (at least 6 weeks after the resolution of the respiratory tract infection).
  • Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a laboratory abnormality or a clinically significant condition such as (but not limited to) unstable ischemic heart disease, cancers, left ventricular failure, long term prednisone therapy, history of myocardial infarction, arrhythmia (all), narrow angle glaucoma, symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment.
  • Patients with a history of asthma indicated by (but not limited to):

    1. Blood eosinophil count > 400/mm3
    2. Onset of symptoms prior to age 40 years.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    NVA237 12.5 µg

    12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.

    Drug: NVA237

  • Experimental
    NVA237 25 µg

    25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.

    Drug: NVA237

  • Experimental
    NVA237 50 µg

    50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.

    Drug: NVA237

  • Experimental
    NVA237 100 µg

    100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.

    Drug: NVA237

  • Placebo comparator
    Placebo

    Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.

    Drug: Placebo

  • Active comparator
    Tiotropium 18 µg

    18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.

    Drug: Tiotropium

Interventions

  • DrugNVA237

    single-dose dry-powder inhaler (SDDPI)

  • DrugPlacebo

    single-dose dry-powder inhaler (SDDPI)

  • Handihaler inhaler

06

What researchers measure

Primary outcomes

  1. Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.

    Time frame: Day 7

Secondary outcomes

  1. Least Squares Means of FEV1 (L) at Day 1, by Timepoint

    FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.

    Time frame: Day 1

07

Results

Posted Jan 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneOverall Study
Started83
Nva237 12.5µg55
Nva237 25µg51
Nva237 50µg53
Nva237 100µg54
Placebo55
Tiotropium55
Completed78
Not completed5
Withdrew: Adverse event3
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryTrough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.

Time frame:
Day 7
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment
LitersNVA237 12.5 ugNVA237 25 ugNVA237 50 ugNVA237 100 ugPlaceboTiotropium Bromide
Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment1.317 ± 0.01451.333 ± 0.01511.374 ± 0.01481.385 ± 0.01481.243 ± 0.01561.370 ± 0.0145
SecondaryLeast Squares Means of FEV1 (L) at Day 1, by Timepoint

FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.

Time frame:
Day 1
Reported as:
Least squares mean · Liters
Least Squares Means of FEV1 (L) at Day 1, by Timepoint
LitersNVA237 12.5 ugNVA237 25 ugNVA237 50 ugNVA237 100 ugPlaceboTiotropium Bromide
Day 1: -45 minutes1.25 ± 0.001.24 ± 0.001.24 ± 0.001.24 ± 0.001.24 ± 0.001.25 ± 0.00
Day 1: -15 minutes1.25 ± 0.001.26 ± 0.001.25 ± 0.001.26 ± 0.001.26 ± 0.001.25 ± 0.00
Day 1: 5 minutes1.30 ± 0.011.34 ± 0.011.34 ± 0.011.35 ± 0.011.26 ± 0.011.31 ± 0.01
Day 1: 15 minutes1.36 ± 0.011.41 ± 0.011.41 ± 0.011.41 ± 0.011.27 ± 0.011.35 ± 0.01
Day 1: 30 minutes1.41 ± 0.011.44 ± 0.011.44 ± 0.011.45 ± 0.011.28 ± 0.011.40 ± 0.01
Day 1: 1 hour1.42 ± 0.011.46 ± 0.011.46 ± 0.011.48 ± 0.011.28 ± 0.011.41 ± 0.01
Day 1: 2 hours1.44 ± 0.011.48 ± 0.011.50 ± 0.011.52 ± 0.011.31 ± 0.011.45 ± 0.01
Day 1: 3 hours1.43 ± 0.011.48 ± 0.011.49 ± 0.011.53 ± 0.011.30 ± 0.011.46 ± 0.01
Day 1: 4 hours1.41 ± 0.011.45 ± 0.011.49 ± 0.011.52 ± 0.011.30 ± 0.011.46 ± 0.01
Day 1: 5 hours1.39 ± 0.011.43 ± 0.011.44 ± 0.011.49 ± 0.011.28 ± 0.011.45 ± 0.01
Day 1: 23 hours 15 minutes1.27 ± 0.011.29 ± 0.011.36 ± 0.011.37 ± 0.011.24 ± 0.011.35 ± 0.01
Day 1: 23 hours 45 minutes1.29 ± 0.011.31 ± 0.011.37 ± 0.011.39 ± 0.011.25 ± 0.011.37 ± 0.01
Trough1.28 ± 0.011.30 ± 0.011.36 ± 0.011.38 ± 0.011.24 ± 0.011.36 ± 0.01

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 12.5 ug—0/55 (0%)6/55 (10.9%)
NVA237 25 ug—0/51 (0%)4/51 (7.8%)
NVA237 50 ug—1/53 (1.9%)1/53 (1.9%)
NVA237 100 ug—0/54 (0%)2/54 (3.7%)
Placebo—0/55 (0%)3/55 (5.5%)
Tiotropium Bromide—0/54 (0%)2/54 (3.7%)
Most frequent serious events
Most frequent serious events
EventNVA237 12.5 ugNVA237 25 ugNVA237 50 ugNVA237 100 ugPlaceboTiotropium Bromide
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/550/511/530/540/550/54
Most frequent other events
Most frequent other events
EventNVA237 12.5 ugNVA237 25 ugNVA237 50 ugNVA237 100 ugPlaceboTiotropium Bromide
HeadacheNervous system disorders4/551/511/531/540/552/54
RhinitisInfections and infestations0/553/510/530/541/550/54
CoughRespiratory, thoracic and mediastinal disorders3/550/510/531/542/550/54

Baseline characteristics

Age Continuous
Age Continuous(years)Overall Study
Mean64.4 ± 9.05
Age, Customized
Age, Customized(participants)Overall Study
40-64 years39
>= 65 years44
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female14
Male69
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian25
Native Hawaiian or Other Pacific Islander0
Black or African American0
White58
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Novartis Investigator Site
    Vilvoorde, Belgium
  • Novartis Investigator Site
    Rueil-Malmaison,, France
  • Novartis Investigator site
    Tokyo, Japan
09

References and documents

Publications

  • Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010 Oct;104(10):1482-9. doi: 10.1016/j.rmed.2010.04.006. Epub 2010 Jun 11. PubMed 20541381 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007 and a primary completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2007
First posted
Jul 16, 2007
Start
Jul 2007
Primary completionActual
Dec 2007
Results first posted
Jan 21, 2011
Last update
May 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00501852
Responsible party
Sponsor
First posted
Jul 16, 2007
Start date
Jul 2007
Primary completion
Dec 2007
Results posted
Jan 21, 2011
Last update
May 8, 2012

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion